MENU
RGC
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

RGC stock forecast, quote, news & analysis

Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people’s immune systems... Show more

RGC
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for RGC with price predictions
Sep 24, 2026

RGC in +7.60% Uptrend, rising for three consecutive days on September 22, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where RGC advanced for three days, in 149 of 172 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 70 cases where RGC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

The Momentum Indicator moved above the 0 level on September 23, 2026. You may want to consider a long position or call options on RGC as a result. In 73 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

RGC moved above its 50-day moving average on September 16, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for RGC crossed bullishly above the 50-day moving average on September 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.

The Aroon Indicator entered an Uptrend today. In 122 of 143 cases where RGC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.

Bearish Trend Analysis

The 10-day RSI Indicator for RGC moved out of overbought territory on September 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 30 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

RGC broke above its upper Bollinger Band on September 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. RGC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: RGC's P/B Ratio (2500.000) is very high in comparison to the industry average of (43.726). P/E Ratio (0.000) is within average values for comparable stocks, (141.424). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.228). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (178.797).

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.12B. The market cap for tickers in the group ranges from 2.12K to 66.28B. MKKGY holds the highest valuation in this group at 66.28B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 3%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 43%. APUS experienced the highest price growth at 195%, while DERM experienced the biggest fall at -14%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 66%. For the same stocks of the Industry, the average monthly volume growth was 124% and the average quarterly volume growth was 89%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 63
Price Growth Rating: 55
SMR Rating: 86
Profit Risk Rating: 82
Seasonality Score: -17 (-100 ... +100)
View a ticker or compare two or three
RGC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Industry
Movies Or Entertainment
Address
29 Leighton Road
Phone
+852 21550823
Employees
10
Web
https://www.regencellbioscience.com
RGC in +7.60% Uptrend, rising for three consecutive days on September 22, 2026